Fig. 6
The effectiveness of MU-CAR-T cells within tumor-bearing mice in vivo. A Flow chart of the experimental design. NCG mice were subcutaneously injected with Karpas 299 lymphoma cells. On Day 9, when the tumor volume reached approximately 100 mm3, control CD8+ T, SdΔN17-28BBZ3-expressing CD8+ T, conventional CAR-T and CD5-CD30-MU-CAR-T cells were intravenously injected into mice respectively, followed by the intraperitoneal injection of IL-7 and IL-15 every 3 days. On Day 24, mice were euthanized and their tumors were collected for subsequent experiments. B Mice from each group were monitored for tumor growth every 3 days. These mice were euthanized at two weeks after infusion of CAR-T cells, and their tumors were collected. Scale bar represented 10 mm. C, D, and E) Mononuclear cells were isolated from collected tumors. Subsequently, the proportion of infiltrating T cells (C) as well as their capabilities of Granzyme B (D) and IFN-γ (E) secretion were evaluated utilizing flow cytometry analysis. F IHC staining results of CD8+ T cells, Granzyme B cytotoxic molecules and IFN-γ cytokines were acquired within tumors derived from various groups. Scale bars represented 50 μm. Data represented as mean ± SD. N = 5 independent biological replicates. Data in (B) were analyzed by two-way ANOVA with Tukey’s multiple comparisons test. Data in (C-E) were analyzed by one-way ANOVA with Tukey’s multiple comparisons test. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001